ReviewCold Spring Harbor perspectives in medicine2015
What Is Next for Retinal Gene Therapy?
Review in Cold Spring Harbor perspectives in medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 13 citations in OpenAlex.
- Progress and prospects of gene therapy in ophthalmology from 2000 to 2022: A bibliometric analysis.Heliyon · 2023Article
- Use of gene therapy for optic nerve protection: Current concepts.Frontiers in neuroscience · 2023Review
- The epigenetic basis for the impaired ability of adult murine retinal pigment epithelium cells to regenerate retinal tissue.Scientific reports · 2019Article
- Notch Signaling-Induced Oscillatory Gene Expression May Drive Neurogenesis in the Developing Retina.Frontiers in molecular neuroscience · 2019Article
- Progress in Gene Therapy to Prevent Retinal Ganglion Cell Loss in Glaucoma and Leber's Hereditary Optic Neuropathy.Neural plasticity · 2018Review
- Nonhuman Primate Studies to Advance Vision Science and Prevent Blindness.ILAR journal · 2017Review
- CRISPR applications in ophthalmologic genome surgery.Current opinion in ophthalmology · 2017Review
- CRISPR-Cas Genome Surgery in Ophthalmology.Translational vision science & technology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
The field of gene therapy for retinal blinding disorders is experiencing incredible momentum, justified by hopeful results in early stage clinical trials for inherited retinal degenerations. The premise of the use of the gene as a drug has come a long way, and may have found its niche in the treatment of retinal disease. Indeed, with only limited treatment options available for retinal indications, gene therapy has been proven feasible, safe, and effective and may lead to durable effects following a single injection. Here, we aim at putting into context the promise and potential, the technical, clinical, and economic boundaries limiting its application and development, and speculate on a future in which gene therapy is an integral component of ophthalmic clinical care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.